Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 5/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2873340 | 0.87 | TSHR (0.45) | KDM4EALDH1A1 | |
| SCHEMBL30278981 | 0.87 | TSHR (0.45) | KDM4EALDH1A1 | |
| SCHEMBL11747828 | 0.86 | HTR2A (0.57) | HTR1ADRD2LMNASMN1; SMN2 | |
| SCHEMBL58391 | 0.84 | KDM4E (0.49) | KDM4ELMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL12016017 | 0.83 | ABCB1 (0.54) | ABCB1HTR1ADRD2ABCG2 | |
| Methoxymethane SCHEMBL19924624 | 0.82 | KDM4E (0.47) | KDM4ELMNASMN1; SMN2ALDH1A1 | |
| Fluoride SCHEMBL28760319 | 0.82 | KDM4E (0.47) | KDM4ELMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL55137 | 0.82 | HTR1A (0.58) | ABCB1HTR1ADRD2SMN1; SMN2ALDH1A1 | |
| SCHEMBL15184061 | 0.78 | TSHR (0.39) | KDM4ELMNAALDH1A1 | |
| SCHEMBL8142708 | 0.77 | TSHR (0.38) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | ABCB1 593/4885HTR1A 4866/4885DRD2 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.